Optimization of a selective calpain-2 inhibitor for prolonged field care in Traumatic Brain Injury

This review examines the therapeutic potential of selective calpain‑2 inhibition as a treatment strategy for traumatic brain injury (TBI). Calpains are calcium‑activated proteases long implicated in neurodegeneration, but previous clinical efforts failed due to insufficient understanding of the distinct roles of individual calpain isoforms. The authors synthesize over a decade of experimental work demonstrating that calpain‑1 and calpain‑2 play opposing roles in the brain following injury.

Calpain‑1 is rapidly and transiently activated after TBI and is shown to be neuroprotective, promoting synaptic plasticity, learning, and memory through activation of survival pathways such as Akt signaling. In contrast, calpain‑2 activation is delayed and prolonged, driving neurodegenerative processes that limit synaptic plasticity and exacerbate neuronal damage. These opposing functions were validated using genetically modified mouse models lacking either calpain‑1 or calpain‑2 in specific neuronal populations.

Building on these mechanistic insights, the authors describe a medicinal chemistry campaign that identified several calpain‑2–selective inhibitors. In multiple animal models of acute neurodegeneration and TBI, these inhibitors reduced lesion size, protected synapses, and improved learning outcomes without disrupting beneficial calpain‑1 activity. One compound, NA‑184, demonstrated favorable brain penetration and neuroprotective efficacy and is currently advancing toward clinical trials for TBI.

The review concludes that isoform‑selective targeting of calpain‑2 represents a promising and mechanistically grounded therapeutic approach for TBI, with potential relevance for other acute neurodegenerative conditions characterized by excitotoxic injury.